Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PRME vs FITZ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRME Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

PRME Overall Winner 6-Pillar Tally: PRME 4 – 1 FITZ (1 Tie) Matrix Metrics: PRME 6 – 2 FITZ

As of Nov 16, 2026, Prime Medicine, Inc. (PRME) is the stronger overall head-to-head candidate over FITZ (FITZ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PRME carries a Unified Composite Score of 52.2/100 (HOLD) at $4.19 (N/M Forward P/E, -2584.2% operating margin), whereas FITZ carries 57.6/100 (HOLD) at $25.44 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While FITZ currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. PRME 52.2/100 HOLD), PRME captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2584.2% vs. N/A operating margin) and revenue trajectory (+243.9% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRME vs FITZ
PRME NASDAQ Head-to-Head Winner
Prime Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.19
-1.87% 1D
Market Cap $949.9M
TTM Revenue $7.1M
Forward P/E N/M
Beta / 30D Vol 2.45β · 149% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.8% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $4.32 · SMA50: $3.71
FITZ US Equity
FITZ
Institutional Equity
$25.44
-2.15% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.00β · 27% Vol
Unified Composite Score
57.6 / 100 HOLD
Tech 45.0 Fund 59.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.0 · SMA20: $26.09 · SMA50: $25.92

6-Pillar Scorecard Institutional Category Breakdown (PRME 4 – 1 FITZ)

Columns: Metric · PRME · FITZ
1. Valuation Multiples PRME
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 143.7x N/M
2. Growth & Scale PRME
Revenue Growth (YoY) +243.9% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $7.1M N/A
Market Cap $949.9M N/A
3. Profitability & Quality PRME
Gross Margin N/A N/A
Operating Margin -2584.2% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -207.2% N/A
4. Balance Sheet & Cash Flow FITZ
Cash Generation (TTM) -$157M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $65M Net Debt (0.06x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRME
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 218.0% (32nd %ile) N/A (N/A)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRME (6) vs FITZ (2)
Institutional Metric PRME FITZ Criterion Row Edge
Market Capitalization
Scale
$949.9M N/A Larger Scale PRME
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+243.9% N/A Higher Growth PRME
Operating Margin (TTM)
Profitability
-2584.2% N/A Higher Margin PRME
Net Profit Margin
Profitability
0.0% N/A Higher Margin PRME
Return on Equity (ROE)
Capital Efficiency
-207.2% N/A Higher ROE PRME
52-Week Range Position
Momentum
47% ($3–$6) 16% ($23–$36) Stronger Trend PRME
Beta / 30D Volatility
Risk Regime
2.45β · 149% Vol 1.00β · 27% Vol Lower Realized Risk FITZ
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 57.6 / 100 (HOLD) Higher Composite FITZ
Trailing 12M Revenue (USD)
Operating Scale
$7.1M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 143.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$157M ($65M Net Debt (0.06x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRME +22.49 pp
PRME: +20.75% · FITZ: -1.74%
3M Horizon PRME +38.28 pp
PRME: +37.38% · FITZ: -0.9%
6M Horizon PRME +22.73 pp
PRME: +23.24% · FITZ: +0.51%
1Y Horizon PRME +22.73 pp
PRME: +23.24% · FITZ: +0.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRME vs FITZ. Trailing 12-month operating profitability (PRME -2584.2% vs FITZ N/A) and valuation multiples (PRME N/M vs FITZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PRME ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.1M
Gross MarginN/A
Op. Margin-2584.2%
ROE / Fwd P/E-207.2% · N/M
FITZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRME SURGE
13d in phase · OBV ACCUMULATION
Current IV 218.0%
IV Percentile 32nd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FITZ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FITZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRME Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $949.9M market capitalization and -2584.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FITZ Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRME vs FITZ Key Questions & Quantitative Answers

As of Nov 16, 2026, Prime Medicine, Inc. (PRME) is the stronger overall head-to-head candidate over FITZ (FITZ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PRME carries a Unified Composite Score of 52.2/100 (HOLD) at $4.19 (N/M Forward P/E, -2584.2% operating margin), whereas FITZ carries 57.6/100 (HOLD) at $25.44 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While FITZ currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. PRME 52.2/100 HOLD), PRME captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2584.2% vs. N/A operating margin) and revenue trajectory (+243.9% vs. N/A YoY).

PRME leads the Growth & Scale pillar: PRME posts +243.9% YoY revenue growth and +0.0% YoY earnings growth on $7.1M TTM revenue (N/A gross margin, -2584.2% operating margin), compared with FITZ at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PRME generates $7.1M in USD-normalized revenue versus N/A for FITZ. In operating R&D and SG&A reinvestment, PRME deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FITZ.

PRME screens cheaper on headline valuation multiples. PRME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 143.7x EV/Revenue (unreported FCF margin), whereas FITZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRME (-207.2% ROE) versus FITZ (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, PRME carries 218.0% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (2.45β · 149% Vol realized risk). By comparison, FITZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.00β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.